- No public price. The consumer app is retired and access runs through partner health systems, insurers or employers.
- Attested
- Not disclosed
- —
- 2017
- US
Mental health
Woebot
by Woebot Health · founded 2017 · US
Chat-based mental health tool. The consumer app was retired on 30 June 2025 and the site now offers provider and payer pages.
On this page
Chat-based mental health tool. The consumer app was retired on 30 June 2025 and the site now offers provider and payer pages.
No public price. The consumer app is retired and access runs through partner health systems, insurers or employers. HIPAA-attested.
Bottom line
The consumer Woebot app, a CBT chatbot patients could download, is gone. Woebot Health retired the app on June 30, 2025, closed transcript requests on July 15, 2025 and anonymized account data as of July 31, 2025. What the company sells now is aimed at providers and payers, and the public site describes it only in broad terms. A clinician cannot buy it for a practice or recommend it to a patient today.
What happened to the Woebot app?
The company's FAQ says the app was retired on June 30, 2025, that new accounts can no longer be created and that previous accounts can no longer be accessed. Alison Darcy, the clinical research psychologist who founded the company in 2017, cited the cost of seeking FDA authorization and the pace at which large language models were moving relative to regulators, according to STAT and other outlets reporting on the shutdown.
What does Woebot Health sell now?
The homepage states a mission of making mental health support radically accessible through chat-based AI wellness tools. The provider page calls Woebot "the behavioral health copilot for Providers" and says the goal is to increase speed to support for patients without increasing clinician burden. It also describes a Woebot Health Platform from which components are used for several products at different development stages and under different regulatory guidance.
The site carries landing pages for provider and payer audiences and for specific health systems, including ChristianaCare, Hackensack Meridian and Virtua Health. Earlier deals included Akron Children's in 2023, a three-year agreement for ages 13 to 17, and Virtua Health in 2024. There is no individual sign-up. The company does not describe the current feature set for payers and providers beyond that, so what a health system receives in 2026 is not public.
What is the regulatory status?
Woebot received an FDA Breakthrough Device designation in May 2021 for WB001, an investigational postpartum depression digital therapeutic. A designation is not clearance or approval, and no FDA clearance for any Woebot product has surfaced. Whether WB001 is still in development is not stated. The homepage shows a HIPAA badge without detail and links a security overview, and EHR integrations, SOC 2 and HITRUST are not stated.
Who funded it?
The company raised an $8 million Series A in 2018 and a $90 million round in 2021 led jointly by JAZZ Venture Partners and Temasek, which the company calls a Series B and HLTH calls a Series C. It also announced $9.5 million from Leaps by Bayer. No acquisition has been reported.
What does the evidence say?
One peer-reviewed paper is clearly about the product: a 2023 JMIR study of user engagement clusters across an 8-week digital mental health intervention guided by Woebot. The title points to usage patterns, not treatment outcomes. A 2025 Iranian Journal of Psychiatry systematic review of AI-powered CBT chatbots mentions Woebot, and the other papers are general AI mental-health reviews. All of it concerns an app that is no longer available.
What does it cost?
Woebot Health publishes no price. Access to the current product goes through a partner health system, insurer or employer.
Who is it for?
Health systems and payers are the buyers. If you run a clinic and a patient asks what to use, Wysa is the closest active alternative named in secondary comparisons, and Limbic and Youper are other options. Check each for its own evidence and regulatory position before recommending it.
The verdict
There is nothing to buy for a practice and nothing to prescribe to a patient. If a health system or payer is pitching you its program, ask for the product description and the evidence, because the public site gives neither.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Provider and payer access | — | — | No public price. The consumer app is retired and access runs through partner health systems, insurers or employers. |
Source: vendor pricing page. Last checked October 15, 2026.
What deploys cleanly
Carries HIPAA per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
Who builds it
Woebot (Woebot Health) was founded in 2017 in US, putting it 9 years into market.
What the literature says
5 peer-reviewed studies indexed on PubMed evaluate Woebot in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- User Engagement Clusters of an 8-Week Digital Mental Health Intervention Guided by a Relational Agent (Woebot): Exploratory Study.
- Hoffman V, Flom M, Mariano TY, et al.· J Med Internet Res· 2023
- With the proliferation of digital mental health interventions (DMHIs) guided by relational agents, little is known about the behavioral, cognitive, and affective engagement components associated with symptom improvement over time. Obtaining a better understanding could lend clues about recommended use for particular subgroups of the population, the potency of different intervention components, and the mechanisms underlying the intervention's success. This exploratory study applied clustering techniques to a range of engagement indicators, which were mapped to the intervention's active compone…
- Effectiveness of a Web-based and Mobile Therapy Chatbot on Anxiety and Depressive Symptoms in Subclinical Young Adults: Randomized Controlled Trial.
- Karkosz S, Szymański R, Sanna K, et al.· JMIR Form Res· 2024
- There has been an increased need to provide specialized help for people with depressive and anxiety symptoms, particularly teenagers and young adults. There is evidence from a 2-week intervention that chatbots (eg, Woebot) are effective in reducing depression and anxiety, an effect that was not detected in the control group that was provided self-help materials. Although chatbots are a promising solution, there is limited scientific evidence for the efficacy of agent-guided cognitive behavioral therapy (CBT) outside the English language, especially for highly inflected languages. This study a…
- Artificial Intelligence-Powered Cognitive Behavioral Therapy Chatbots, a Systematic Review.
- Farzan M, Ebrahimi H, Pourali M, et al.· Iran J Psychiatry· 2025
- This review identifies the characteristic features of artificial intelligence (AI) chatbots and their therapeutic effect; assesses their efficacy in treatment of depression, anxiety, and other mental health disorders; and establishes levels of user engagement and satisfaction.Searches were conducted on the PubMed, Embase, MEDLINE, CENTRAL, CINAHL, PsycINFO, and Google Scholar databases using a set of keywords such as, not limited to, AI cognitive behavioral therapy (AI CBT), Youper, Wysa, Woebot, and other related terms. We included studies that were empirical, peer-reviewed, conducted betwee…
- Effectiveness of artificial intelligence chatbots on mental health & well-being in college students: a rapid systematic review.
- Nyakhar S, Wang H· Front Psychiatry· 2025
- Mental health disorders among college students have surged in recent years, exacerbated by barriers such as stigma, cost associated with treatment, and limited access to mental health providers. Artificial intelligence (AI)-driven chatbots have emerged as scalable, stigma-free tools to deliver evidence-based mental health support, yet their efficacy specifically for college populations remains underexplored. This systematic rapid review evaluates the effectiveness of chatbots in improving mental health outcomes (e.g., anxiety, depression) and well-being among college students while identifyin…
- Network-based artificial intelligence in mental healthcare: A systematic review of chatbots, artificial intelligence/machine learning models and ethical considerations in global healthcare networks.
- Rezaei Z, Khorraminia A, Shi D, et al.· Digit Health· 2026
- This systematic review examines how artificial intelligence (AI), including machine learning (ML) models and AI-powered chatbots, contributes to the diagnosis, treatment and ethical governance of mental healthcare. It explores how AI-driven systems form interconnected healthcare networks that enhance accessibility, personalization and resilience of mental health services, aligning with the United Nations Sustainable Development Goal 3: Good Health and Well-Being. A comprehensive search across PubMed, IEEE Xplore and Google Scholar (2017-2024) was conducted using Boolean combinations of "AI,"…
Other mental health
See the full mental health ranking
Headspace
by Headspace Inc.
Meditation, sleep and mindfulness app with Ebb, an AI companion for paid members that recommends Headspace content.
$12.99/mo
Mentalyc
by Mentalyc Inc.
Therapy-specific AI note generator (DAP/SOAP/BIRP/GIRP).
$19.99-119.99/mo.|HIPAA
Eleos Health
by Eleos Health
Documentation, compliance review and revenue-cycle platform for community-based behavioral health care.
No public price. Custom quote at organization level after a demo request.|HIPAA / SOC2 Type II
Wysa
by Wysa Inc.
CBT/DBT/mindfulness chatbot ("penguin"), NHS-deployed.
Free + ~$74.99/yr Premium.|HIPAA / GDPR